Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
NRG Oncology
Insel Gruppe AG, University Hospital Bern
Fudan University
Covenant Health Cancer Center
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris
Tehran University of Medical Sciences
Tata Memorial Hospital
Groupe Oncologie Radiotherapie Tete et Cou
All India Institute of Medical Sciences
Tehran University of Medical Sciences